Rhythm Pharmaceuticals saw the highest growth of 2.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Rhythm Pharmaceuticals’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Rhythm Pharmaceuticals has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 40% of filings. The World Intellectual Property Organization(WIPO), Denmark(DK), European Patent Office(EPO), and Finland(FI) patent Office are among the top ten patent offices where Rhythm Pharmaceuticals is filings its patents. Among the top granted patent authorities, Rhythm Pharmaceuticals has 50% of its grants in Finland(FI) and 50% in Portugal(PT).
Novo Nordisk Foundation and Novartis could be the strongest competitors for Rhythm Pharmaceuticals
Obesity related patents lead Rhythm Pharmaceuticals portfolio followed by prader-willi syndrome (pws), and hyperinsulinemia
Rhythm Pharmaceuticals has highest number of patents in obesity followed by prader-willi syndrome (pws), hyperinsulinemia, diabetes, and glucose intolerance. For obesity, nearly 27% of patents were filed and 17% of patents were granted in Q2 2024.
For comprehensive analysis of Rhythm Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

